FDA Panel Backs Donanemab: New Hope for Early Alzheimer’s Treatment
Eli Lilly’s Alzheimer’s drug, Donanemab, has received a recommendation for FDA approval from an independent panel.
The drug has shown significant promise in slowing the progression of early-stage Alzheimer’s,
Source:
About Neuroscience News
Official Neuroscience News Twitter. Brain research news articles on neuroscience, psychology, AI, neurology, brain cancer, robotics, mental health & science.